From the Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Kepler University, Linz, Austria (MH, HG, BH-E, JM), Department of Anesthesiology and Critical Care Medicine, University and University Hospital Zürich, Zürich, Switzerland (AH) and Department of Orthopaedics, Faculty of Medicine, Kepler University, Linz, Austria (NB).
Eur J Anaesthesiol. 2018 Apr;35(4):289-297. doi: 10.1097/EJA.0000000000000752.
Pre-operative anaemia and transfusion are common among patients undergoing elective orthopaedic surgery. Application of 'patient blood management' might be the most effective way to reduce both anaemia and transfusion. Pre-operative administration of iron and/or erythropoietin (EPO) is one of the cornerstones of the first pillar of patient blood management, but in a daily clinical setting, efficacy and long-term safety of this measure have not been analysed thoroughly to date.
To investigate the influence of pre-operative preparation (PREP) of patients with iron and/or EPO on peri-operative transfusion needs and long-term survival.
Single-centre, retrospective study.
Anaesthesia department, University hospital.
Pre-operative preparation with iron and/or EPO versus no preparation.
After approval of our local ethics committee, data of 5518 patients who received total hip or total knee replacement between 2008 and 2014 were included. Patients receiving iron and/or EPO were included in the PREP group, whereas patients without iron and/or EPO were included in the no preparation group. From the full data set, a bias-reduced subset of 662 patients was obtained by means of propensity score-matching to compare peri-operative red blood cell utilisation and long-term survival of patients between groups.
Patients in the PREP group needed a lower number of units of red blood cells than patients in the no preparation group (0.2 ± 0.8 vs. 0.5 ± 1.3, P < 0.001), had a lower transfusion rate (12 vs. 24%, P < 0.05) and had a similar haemoglobin concentration (10.7 ± 1.3 vs. 10.6 ± 1.1 g dl, not significant) at discharge. No differences in long-term survival were observed between the two study groups.
PREP of patients with iron and/or EPO in orthopaedic patients can be considered highly effective in terms of transfusion reduction, without influencing long-term survival.
择期行骨科手术的患者常伴有术前贫血和输血。应用“患者血液管理”可能是减少贫血和输血的最有效方法。术前给予铁剂和/或促红细胞生成素(EPO)是患者血液管理第一大支柱的基石之一,但在日常临床实践中,该措施的疗效和长期安全性尚未得到充分分析。
研究术前给予铁剂和/或 EPO 对围手术期输血需求和长期生存的影响。
单中心回顾性研究。
大学医院麻醉科。
术前给予铁剂和/或 EPO 与不给予铁剂和/或 EPO 比较。
在获得我们当地伦理委员会批准后,纳入了 2008 年至 2014 年间接受全髋关节或全膝关节置换术的 5518 例患者的数据。接受铁剂和/或 EPO 的患者被纳入 PREP 组,而未接受铁剂和/或 EPO 的患者被纳入无准备组。从完整数据集通过倾向评分匹配获得了一个偏倚降低的 662 例患者子集,以比较两组患者围手术期红细胞利用情况和长期生存。
PREP 组患者需要的红细胞单位数少于无准备组(0.2±0.8 比 0.5±1.3,P<0.001),输血率较低(12%比 24%,P<0.05),出院时血红蛋白浓度相似(10.7±1.3 比 10.6±1.1 g/dl,无统计学差异)。两组患者的长期生存率无差异。
在骨科患者中,术前给予铁剂和/或 EPO 可有效减少输血,而不影响长期生存。